Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization-Reference-Cited by-同舟云学术

Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Published:2016-04-07 Issue: Volume:2016 Page:1-9
ISSN:0894-8569
Container-title:HPB Surgery
language:en
Short-container-title:HPB Surgery

Author:

Ahmed Saleem¹²,de Souza Nurun Nisa³⁴,Qiao Wang²,Kasai Meidai⁵,Keem Low Jee¹,Shelat Vishal G.¹

Affiliation:

1. Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433

2. Ministry of Health Holdings, 1 Maritime Square, Singapore 099253

3. Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857

4. Singapore Clinical Research Institute, 31 Biopolis Way, Singapore 138669

5. Department of Gastroenterological Surgery, Sendai Kousei Hospital, 8-15 Hirosemachi, Aoba-ku, Sendai-shi, Miyagi 9800873, Japan

Abstract

Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers worldwide. Majority of patients with HCC are diagnosed in the advanced stages of disease and hence they are only suitable for palliative therapy. TACE (transarterial chemoembolization) is the most commonly used treatment for unresectable HCC. It is however unclear if TACE improves the quality of life (QoL) in patients with HCC. The aim of this review is to evaluate the impact of TACE on QoL of HCC patients.

Publisher

Hindawi Limited

Subject

Hepatology,Surgery

Link

http://downloads.hindawi.com/archive/2016/6120143.pdf

Reference42 articles.

1. Epidemiology of Hepatocellular Carcinoma

2. Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization

3. Measuring Health-Related Quality of Life in Patients With Hepatobiliary Cancers: The Functional Assessment of Cancer Therapy–Hepatobiliary Questionnaire

4. Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients

5. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of PIVKA-II and AFP for the non-objective response of HBV-associated hepatocellular carcinoma after transarterial chemoembolization: a prospective study;European Journal of Gastroenterology & Hepatology;2023-10-25

2. Preoperative transarterial chemoembolization (TACE) + liver resection versus upfront liver resection for large hepatocellular carcinoma (≥5 cm): a systematic review and meta-analysis;Acta Chirurgica Belgica;2023-09-08

3. Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil;Journal of Medical Economics;2023-05-24

4. The impact of symptom distress on health-related quality of life in liver cancer patients receiving arterial chemoembolization: the mediating role of hope;BMC Gastroenterology;2022-11-15

5. Effect of music therapy on postembolization syndrome in Thai patients with hepatocellular carcinoma: A quasi-experimental crossover study;Belitung Nursing Journal;2022-10-21